GA²LEN

GA²LEN, the Global Allergy and Asthma European Network, was created to combat fragmentation in the European research area, ensuring excellence in EU allergy and asthma research by bringing together institutions and researchers from across the EU. The network notably put in place centralized structures and an office overseeing the multiple assets in knowledge in the different GA²LEN partners, enabling them to optimally synchronize their research efforts.

GA²LEN is now recognized worldwide as the EU’s groundbreaking allergy organization.

GA²LEN’s vision is further reduce the burden of allergic diseases in Europe by improving the health of European Citizens with allergic diseases; increasing the competitiveness and boosting the innovative capacity of EU health-related industries and businesses while addressing health issues including emerging allergies.

To this end GA²LEN has launched a program for the development, interaction and accreditation of centers of reference and excellence in special areas of allergy. These centers are specialized in

Angioedema (ACARE)

as well as

Urticaria (UCARE)

Atopic Dermatitis (ADCARE)

Anaphylaxis (ANACARE)

Allergic Rhinitis (ARIACARE)

ACARE

Since its inception in December of 2019, the ACARE network has grown to over 70 member centers in more than 34 countries. Today it is the biggest and most active consortium of angioedemologists and angioedema centers with the largest global reach to patients affected by angioedema and its comorbidities.

Our co-initiator and partner HAEi is a global non-profit network of patient associations dedicated to improving the lives of people with HAE. They provide their member organizations with specially designed tools and technical assistance that promote disease education and support activities addressing the unique needs of HAE patients and their families.

Together, ACARE and HAEi are committed to to increase the quality of life of all patients affected by angioedema by excellent medical care and research that improves our understanding of angioedema and its treatment. We also want to grow awareness of the disease, its symptoms, comorbidities, burden, its diagnostic workup, and treatment options, thereby empowering both patients and physicians to take control of all aspects of angioedema.

Please read our Charter for more information on our governance structure.

Steering Committee

Prof. Dr. Marcus Maurer – Germany

Prof. Dr. Markus Magerl – Germany

Prof. Dr. Henriette Farkas – Hungary

Prof. Dr. Anete S. Grumach – Brazil